

Summary of Studies Supporting USDA Product Licensure

Establishment Name	Elanco US Inc.
USDA Vet Biologics Establishment Number	196
Product Code	4465.20
True Name	Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3- Respiratory Syncytial Virus Vaccine, Killed Virus, Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae- Pomona Bacterin
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Vira Shield 6 + L5 HB - Elanco Canada Limited - Elanco US Inc. Vira Shield 6 + L5 HB - Elanco US Inc. Vira Shield 6 + L5 HB - Elanco, Division Eli Lilly Canada, Inc Elanco US Inc. Vira Shield 6 + L5 HB - No distributor specified
Date of Compilation Summary	August 31, 2020

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

Study Type	Efficacy
Pertaining to	Bovine Virus Diarrhea (BVD)
Study Purpose	To demonstrate effectiveness against Bovine Virus Diarrhea
	Type 1b
Product Administration	
Study Animals	Bovine
Challenge Description	BVD isolate NY-1, BVD1b
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only require publication of data submitted after that date.
USDA Approval Date	July 16, 2003

S4 J T						
Study Type	Efficacy					
Pertaining to	Bovine Virus Diarrhea (BVD)					
Study Purpose	To demonstrate effectiveness against Bovine Virus Diarrhea					
	Type 2a					
Product Administration						
Study Animals	Bovine					
Challenge Description	BVD isolate 890, Type BVD2a					
Interval observed after						
challenge						
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only require publication of data submitted after that date.					
USDA Approval Date	November 3, 1998					

Study Type	Efficacy
Pertaining to	Bovine Virus Diarrhea
Study Purpose	To demonstrate effectiveness against Bovine Virus Diarrhea
	Type 2a at 11 months post-vaccination
Product Administration	
Study Animals	Bovine
Challenge Description	BVD Isolate 890, Type BVD2a
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only require publication of data submitted after that date.
USDA Approval Date	September 24, 1996

Study Type	Efficacy
Pertaining to	Bovine Rhinotracheitis
Study Purpose	To demonstrate effectiveness against Bovine Rhinotracheitis.
Product Administration	
Study Animals	Bovine
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only require publication of data submitted after that date.
USDA Approval Date	October 22, 1986

Ctor des Terres	
Study Type	Efficacy
Pertaining to	Leptospira canicola, Leptospira grippotyphosa, Leptospira
	icterohaemorrhagiae, Leptospira pomona
Study Purpose	To demonstrate effectiveness against Leptospira spp.
Product Administration	
Study Animals	Bovine
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only require publication of data submitted after that date.
USDA Approval Date	March 18, 1983

G4 1 T	
Study Type	Efficacy
Pertaining to	Leptospira hardjo type hardjo-bovis
Study Purpose	To demonstrate effectiveness against Leptospira hardjo type
	hardjo-bovis
Product Administration	
Study Animals	Bovine
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only require publication of data submitted after that date.
USDA Approval Date	July 24, 2001 / November 9, 2001

Study Type	Efficacy						
Pertaining to	Leptospira hardjo type hardjo-bovis						
Study Purpose	To demonstrate effectiveness against <i>Leptospira hardjo</i> type						
	hardjo-bovis at 12 months post vaccination.						
Product Administration	Two doses, given su	bcutaneously, 28 days	apart				
Study Animals	18 vaccinates and 18	8 placebo controls					
Challenge Description	L. hardjo Bovis (10 ⁷ bacteria/1 mL) administered 397 days after first vaccination.						
Interval observed after	Observed daily after	challenge for 57 days.	Tissues and organs				
challenge	evaluated at 57 days	post challenge.	-				
Results	The primary outcome for the study was the isolation of L. hardjo bovis organisms from urine, kidney, and reproductive tissues.						
	VaccinatesControls(# affected/total)(# affected/total)						
	Urine isolation	4/18	18/18				
	Kidney isolation	0/18	18/18				
	Reproductive tissues isolation0/185/18						
	Raw data shown on attached page.						
USDA Approval Date	February 14, 2011						

	Vaccinates								
Calf	-1DPC	7DPC	14DPC	21DPC	28DPC	35DPC	42DPC	49DPC	56DPC
1	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
2	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
3	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
4	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
5	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Pos
6	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
7	Neg	Neg	Neg	Neg	Neg	Neg	Pos	Neg	Neg
8	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
9	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
10	Neg	Neg	Neg	Neg	Pos	Neg	Neg	Neg	Neg
11	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
12	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
13	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
14	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
15	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
16	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg
17	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Pos	Neg
18	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg

	Controls								
Calf	-1DPC	7DPC	14DPC	21DPC	28DPC	35DPC	42DPC	49DPC	56DPC
1	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos	Pos
2	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos	Pos
3	Neg	Neg	Neg	Neg	Pos	Pos	Neg	Pos	Pos
4	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos	Pos
5	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos	Pos
6	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos
7	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos
8	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos
9	Neg	Neg	Neg	Pos	Pos	Pos	Neg	Pos	Pos
10	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos
11	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos	Pos
12	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos	Pos
13	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos
14	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos
15	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos	Pos
16	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos
17	Neg	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos
18	Neg	Neg	Neg	Pos	Pos	Pos	Pos	Pos	Pos

DPC - Days Post Challenge

Pos - Positive Isolation of L. Hardjo

Neg - No Isolation of L. Hardjo

Vaccinates								
Calf	Kidney	Ovary	Oviduct	Uterus				
1	Neg	Neg	Neg	Neg				
2	Neg	Neg	Neg	Neg				
3	Neg	Neg	Neg	Neg				
4	Neg	Neg	Neg	Neg				
5	Neg	Neg	Neg	Neg				
6	Neg	Neg	Neg	Neg				
7	Neg	Neg	Neg	Neg				
8	Neg	Neg	Neg	Neg				
9	Neg	Neg	Neg	Neg				
10	Neg	Neg	Neg	Neg				
11	Neg	Neg	Neg	Neg				
12	Neg	Neg	Neg	Neg				
13	Neg	Neg	Neg	Neg				
14	Neg	Neg	Neg	Neg				
15	Neg	Neg	Neg	Neg				
16	Neg	Neg	Neg	Neg				
17	Neg	Neg	Neg	Neg				
18	Neg	Neg	Neg	Neg				

Isolation of L. Hardjo in Kidney and Reproductive tissues

Controls					
Calf	Kidney	Ovary	Oviduct	Uterus	
1	Pos	Neg	Neg	Neg	
2	Pos	Neg	Neg	Neg	
3	Pos	Neg	Neg	Neg	
4	Pos	Neg	Neg	Neg	
5	Pos	Neg	Pos	Neg	
6	Pos	Neg	Neg	Neg	
7	Pos	Pos	Neg	Neg	
8	Pos	Neg	Neg	Neg	
9	Pos	Pos	Pos	Neg	
10	Pos	Neg	Neg	Neg	
11	Pos	Neg	Neg	Neg	
12	Pos	Neg	Neg	Neg	
13	Pos	Pos	Neg	Neg	
14	Pos	Pos	Neg	Neg	
15	Pos	Neg	Neg	Neg	
16	Pos	Neg	Neg	Neg	
17	Pos	Neg	Neg	Neg	
18	Pos	Neg	Neg	Neg	

Pos-Positive Isolation of L. hardjo

Neg – No isolation of L. hardjo

Study Type	Efficacy
Pertaining to	Bovine Parainfluenza Type 3
Study Purpose	To demonstrate effectiveness against Bovine Parainfluenza Type
	3.
Product Administration	
Study Animals	Bovine
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only require publication of data submitted after that date.
USDA Approval Date	March 12, 1987 (License Issued)

Study Type	Efficacy
Pertaining to	Bovine Respiratory Syncytial Virus
Study Purpose	To demonstrate effectiveness against Bovine Respiratory
	Syncytial Virus
Product Administration	
Study Animals	Bovine
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only require publication of data submitted after that date.
USDA Approval Date	December 18, 1987

Study Type	Safety
Pertaining to	All fractions
Study Purpose	Safety by SQ route in cattle, including pregnant cows and heifers
Product Administration	
Study Animals	
Challenge Description	
Interval observed after	
challenge	
Results	Scientific data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission.

a. 1 m	
Study Type	Safety
Pertaining to	All fractions
Study Purpose	To demonstrate safety under field conditions
Product Administration	
Study Animals	Bovine, including pregnant cows and heifers
Challenge Description	
Interval observed after	
challenge	
Results	Scientific data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. However, study data are not available.